Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSX01-TCRT in Refractory/Relapsed Solid Tumors
NCT05811975Phase 1Recruiting
- Sponsor
- TScan Therapeutics, Inc.
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Bone Marrow HSCs, HLA-independent TCR-T, Allogeneic CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KSX01 in solid tumor, sponsored by TScan Therapeutics, Inc. Primary endpoints: Subject safety at 2 years and Tumor efficacy at 2 years. Started Mar 2023; status: recruiting.
02
Drugs
KSX01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05811975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05811975.